storage is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
== Public consumption == The center at the Ames Research Center in California began researching how to allow visitors to taste astronaut food in 1973. They contacted American Outdoor Products and Backpacker's Pantry, the latter becoming a known source for freeze-dried meals like stews and even pasta dishes for serious campers and backpackers. NASA/AMES worked with American Outdoor Products to produce the world first freeze-dried ice cream and Astronaut Foods with the goal to allow people to see what space food tastes like.
=== Cold War tensions and the border militarisation === The increasing likelihood of armed conflict in South West Africa had strong international foreign policy implications, for both Western Europe and the Soviet bloc. Prior to the late 1950s, South Africa's defence policy had been influenced by international Cold War politics, including the domino theory and fears of a conventional Soviet military threat to the strategic Cape trade route between the south Atlantic and Indian oceans. Noting that the country had become the world's principal source of uranium, the South African Department of External Affairs reasoned that "on this account alone, therefore, South Africa is bound to be implicated in any war between East and West". Prime Minister Malan took the position that colonial Africa was being directly threatened by the Soviets, or at least by Soviet-backed communist agitation, and this was only likely to increase whatever the result of another European war. Malan promoted an African Pact, similar to NATO, headed by South Africa and the Western colonial powers accordingly. The concept failed due to international opposition to apartheid and suspicion of South African military overtures in the British Commonwealth. South Africa's participation in the Korean War produced a significant warming of relations between Malan and the United States, despite American criticism of apartheid. Until the early 1960s, South African strategic and military support was considered an integral component of U.S.
microtubule Any of the long, generally straight, hollow tubes, about 24 nanometers in diameter and composed of interwoven polymeric filaments of the protein tubulin, found in the cytoplasm of many eukaryotic cells, where they are involved in maintaining the cell's shape and structural integrity as well as in force generation for cellular or organellar locomotion (as with cilia and flagella). They also comprise the spindle apparatus critical to mitosis and meiosis. Microtubules are rigid but transient all-purpose structural members which can be rapidly assembled and disassembled at the cell's needs. Many different microtubule-associated proteins interact with them. See also microfilament.
Reported side effects are: neurological reactions (e.g., headache, dizziness, drowsiness, disorientation, hallucinations, and convulsions), nausea, vomiting, diarrhea, constipation, mucositis, anorexia, stomatitis, bone marrow toxicity (dose-limiting toxicity; may take 7–21 days to recover after the drug has been discontinued), megaloblastic anemia, thrombocytopenia, bleeding, hemorrhage, gastrointestinal ulceration and perforation, immunosuppression, leukopenia, alopecia (hair loss), skin rashes (e.g., maculopapular rash), erythema, pruritus, vesication or irritation of the skin and mucous membranes, pulmonary edema, abnormal liver enzymes, creatinine and blood urea nitrogen. Due to its negative effect on the bone marrow, regular monitoring of the full blood count is vital, as well as early response to possible infections. In addition, renal function, uric acid and electrolytes, as well as liver enzymes, are commonly checked. Moreover, because of this, its use in people with leukopenia, thrombocytopenia or severe anemia is contraindicated. Hydroxycarbamide has been used primarily for the treatment of myeloproliferative diseases, which has an inherent risk of transforming to acute myeloid leukemia. There has been a longstanding concern that hydroxycarbamide itself carries a leukemia risk, but large studies have shown that the risk is either absent or very small. Nevertheless, it has been a barrier for its wider use in patients with sickle-cell disease.
Sources: en.wikipedia.org
== Limitations == Along with the emerging diagnostic capabilities of pharmacometabolomics, there are limitations introduced when individual variability is looked at. The ability to determine an individual's physiological state by measurement of metabolites is not contested, but the extreme variability that can be introduced by age, nutrition, and commensal organisms suggest problems in creating generalized pharmacometabolomes for patient groups. However, as long as meaningful metabolic signatures can be elucidated to create baseline values, there still exists a possible means of comparison. Issues surrounding the measurement of metabolites in an individual can also arise from the methodology of metabolite detection, and there are arguments both for and against NMR and mass spectrometry (MS). Other limitations surrounding metabolite analysis include the need for proper handling and processing of samples, as well as proper maintenance and calibration of the analytical and computational equipment. These tasks require skilled and experienced technicians, and potential instrument repair costs due to continuous sample processing can be costly. The cost of the processing and analytical platforms alone is very high, making it difficult for many facilities to afford pharmacometabolomics-based treatment analyses.
In September 2016, when asked if he thought the world had entered a new cold war, Russian Foreign Minister, Sergey Lavrov, argued that current tensions were not comparable to the Cold War. He noted the lack of an ideological divide between the United States and Russia, saying that conflicts were no longer ideologically bipolar. In August 2016, Daniel Larison of The American Conservative magazine wrote that tensions between Russia and the United States would not "constitute a 'new Cold War'" especially between democracy and authoritarianism, which Larison found more limited than and not as significant in the 2010s as that of the Soviet-Union era. Andrew Kuchins, an American political scientist and Kremlinologist speaking in December 2016, believed the term was "unsuited to the present conflict" as it may be more dangerous than the Cold War. In October 2016, John Sawers, a former MI6 chief, said he thought the world was entering an era that was possibly "more dangerous" than the Cold War, as "we do not have that focus on a strategic relationship between Moscow and Washington". Similarly, Igor Zevelev, a fellow at the Wilson Center, said that "it's not a Cold War [but] a much more dangerous and unpredictable situation". CNN opined: "It's not a new Cold War. It's not even a deep chill. It's an outright conflict", due to "competing military operations in Syria, disputes over Eastern European independence and escalating cyber breaches". In January 2017, former US government adviser Molly K.
The dog is neither wholly carnivorous nor wholly herbivorous, but of a mixed kind, and can receive nourishment from either flesh or vegetables. A mixture of both is therefore his proper food, but of the former he requires a greater portion, and this portion should be always determined by his bodily exertions. It was not until the mid-1800s that the world saw its first food made specifically for dogs. An American electrician, James Spratt, concocted the first dog treat. Living in London at the time, he witnessed dogs around a shipyard eating scraps of discarded biscuits. Shortly thereafter he introduced his dog food, made up of wheat meals, vegetables and meat. By 1890 production had begun in the United States and became known as "Spratt's Patent Limited". In later years, dog biscuit was sometimes treated as synonymous with dog food:
Sources: en.wikipedia.org
==== Non-selective ==== α-MSH β-MSH γ-MSH ACTH Afamelanotide Bremelanotide Melanotan II Modimelanotide Setmelanotide — MC4 receptor agonist which is FDA approved to help with chronic weight management in those with pathogenic (or uncertain) variants in POMC and certain related genes.
=== Multi State cooperative Society === Any society that is formed with the object of the economic and social improvement of its members by way of self-help groups with mutual aid, but is registered in more than one state is known as Multi State Cooperative Society.
=== Main characters === Frank Poole: 3001's protagonist, Frank Poole has been revived by highly advanced medicine, a thousand years after being killed by HAL during the Discovery's original mission. Dr. Indra Wallace: A specialist on the history of the early twenty-first century, Wallace acts as Poole's cultural guide. Halman: a merging of the entities that were once HAL 9000 and Dave Bowman, Halman communicates with Poole at various points throughout the novel, warning Poole of the possibility that the monoliths may issue negative judgment against humanity.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.